Neutrophil gelatinase-associated lipocalin predicts the efficacy of tolvaptan for ascites in patients with liver cirrhosis

J Gastroenterol. 2023 Jul;58(7):656-667. doi: 10.1007/s00535-023-01993-w. Epub 2023 Apr 27.

Abstract

Background: Acute kidney injury (AKI) is associated with liver cirrhosis (LC), water retention, diuretics to treat water retention, and a poor prognosis. Urinary neutrophil gelatinase-associated lipocalin (uNGAL) reportedly predicts a poor prognosis in decompensated LC. This study investigated the usefulness of uNGAL in predicting the short- and long-term effects of tolvaptan (TVP) and the incidence of AKI post-TVP administration.

Methods: Of the LC cases with water retention, 86 with available pre-treatment uNGAL were analyzed. A short-term response was defined as weight loss of ≥ 1.5 kg within the first week; a long-term response was defined as a short-term response without early recurrence. The uNGAL usefulness in predicting the short- and long-term effects of TVP and AKI incidence post-TVP administration was investigated.

Results: Short-term effects of TVP were observed in 52 patients. Of these, 15 patients had an early recurrence. In multivariate analysis, significant short-term predictive factors were C-reactive protein (CRP) < 1.4 mg/dl, uNa/K ratio ≥ 3.51, and uNGAL < 50.2 ng/ml. Patients were classified according to these three cut-off values, with short-term response rates of 92.9%, 68.8%, 26.7%, and 0% for 0, 1, 2, and 3 points, respectively. CRP < 0.94 mg/dl and uNGAL < 50.2 ng/ml were significant factors for predicting the long-term response of TVP. The AKI incidence post-TVP was 8.1% (n = 7) and was significantly higher among those with uNGAL ≥ 38.1 ng/mL.

Conclusion: uNGAL is a useful predictor of the short- and long-term efficacy of TVP and can be useful in predicting AKI incidence post-TVP administration.

Keywords: Acute kidney injury; Liver cirrhosis; Neutrophil gelatinase-associated lipocalin; Tolvaptan; Water retention.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Kidney Injury* / chemically induced
  • Acute-Phase Proteins* / metabolism
  • Ascites / complications
  • Ascites / etiology
  • Biomarkers
  • C-Reactive Protein / metabolism
  • Humans
  • Lipocalin-2
  • Lipocalins / metabolism
  • Liver Cirrhosis / complications
  • Proto-Oncogene Proteins
  • Tolvaptan / therapeutic use
  • Water / metabolism

Substances

  • Lipocalin-2
  • Tolvaptan
  • Acute-Phase Proteins
  • Lipocalins
  • Proto-Oncogene Proteins
  • Biomarkers
  • C-Reactive Protein
  • Water